Evidence map›Paper›PMID 40918650›Full record

ArticleNAR cancer2025

ABL1-mediated tyrosine phosphorylation of SYCP2 contributes to transcription-coupled homologous recombination and platinum resistance in ovarian cancer.

Boya Gao, Xudong Wang, Melissa Long, Fengqi Zhang, Yumin Wang, Raj Kumar, Irva Veillard, Bo R Rueda, Oladapo Yeku, Li Lan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Boya GaoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, 213 Research Drive, Durham, NC 27710, United States.
Xudong WangMassachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, MA 02129, United States.
Melissa LongDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, 213 Research Drive, Durham, NC 27710, United States.
Fengqi ZhangDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, 213 Research Drive, Durham, NC 27710, United States.
Yumin WangMassachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, MA 02129, United States.
Raj KumarDivision of Hematology-Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States.
Irva VeillardDivision of Hematology-Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States.
Bo R RuedaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States.
Oladapo YekuDivision of Hematology-Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States.
Li LanDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, 213 Research Drive, Durham, NC 27710, United States.ORCID 0000-0003-0383-6172

Funding

Understanding and Targeting the R-Loop-Mediated DNA Damage Response at TelomeresR01CA282939 · NCI · DUKE UNIVERSITY · PI Li Lan · 2023 to 2026
$1.5M
NCI NIH HHS R01 CA282939
6 · The paper itself

Abstract

Treatment of patients with platinum-resistant ovarian cancer is a major clinical challenge. We found that high expression of a meiotic protein, Synaptonemal Complex Protein 2 (SYCP2), is associated with platinum resistance and tyrosine kinase ABL1 inhibitor sensitivity in ovarian cancer. We demonstrate that tyrosine kinase ABL1 inhibitors inhibit cancer cell proliferation more efficiently in ovarian cancer cell lines with SYCP2 overexpression. Moreover, ABL1 inhibition effectively prevents tumor growth

Indexed as

Drug Resistance, NeoplasmHomologous RecombinationOvarian NeoplasmsProto-Oncogene Proteins c-ablAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationFemaleHumansMicePhosphorylationProtein Kinase InhibitorsRad51 RecombinaseTranscription, GeneticTyrosineABL1 protein, humanAntineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-ablRAD51 protein, humanRad51 RecombinaseTyrosine

Identifiers

PMID40918650
PMCPMC12409405

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.